Kristen Ambrose - 25 Apr 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
SVP & Chief Accounting Officer
Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
25 Apr 2022
Net transactions value
-$88,143
Form type
4
Filing time
27 Apr 2022, 16:05:27 UTC
Previous filing
05 Apr 2022
Next filing
03 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Sale $16,042 -60 -1.6% $267.37 3,763 25 Apr 2022 Direct F1, F2, F3
transaction VRTX Common Stock Sale $21,477 -80 -2.1% $268.46 3,683 25 Apr 2022 Direct F1, F2, F4
transaction VRTX Common Stock Sale $22,369 -83 -2.3% $269.51 3,600 25 Apr 2022 Direct F1, F2, F5
transaction VRTX Common Stock Sale $28,255 -104 -2.9% $271.68 3,496 25 Apr 2022 Direct F1, F2, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1.
F2 Ms. Ambrose undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $267.37 (range $266.86 to $267.85).
F4 Open market sales reported on this line occurred at a weighted average price of $268.46 (range $268.05 to $268.86).
F5 Open market sales reported on this line occurred at a weighted average price of $269.51 (range $269.12 to $269.90).
F6 Open market sales reported on this line occurred at a weighted average price of $271.68 (range $271.25 to $272.23).